CN117554615A - ADAMTS13 enzyme activity luminescence immunoassay method and ADAMTS13 enzyme activity assay kit - Google Patents
ADAMTS13 enzyme activity luminescence immunoassay method and ADAMTS13 enzyme activity assay kit Download PDFInfo
- Publication number
- CN117554615A CN117554615A CN202410044447.2A CN202410044447A CN117554615A CN 117554615 A CN117554615 A CN 117554615A CN 202410044447 A CN202410044447 A CN 202410044447A CN 117554615 A CN117554615 A CN 117554615A
- Authority
- CN
- China
- Prior art keywords
- reagent
- enzyme activity
- adamts13
- kit
- adamts13 enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091005670 ADAMTS13 Proteins 0.000 title claims abstract description 69
- 230000000694 effects Effects 0.000 title claims abstract description 52
- 238000004020 luminiscence type Methods 0.000 title claims abstract description 34
- 102000043853 ADAMTS13 Human genes 0.000 title claims abstract 26
- 238000003018 immunoassay Methods 0.000 title claims description 23
- 238000001952 enzyme assay Methods 0.000 title claims description 5
- 239000006249 magnetic particle Substances 0.000 claims abstract description 52
- 238000001514 detection method Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims description 65
- 239000000758 substrate Substances 0.000 claims description 25
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 24
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000003908 quality control method Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 claims 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims 2
- 229910052707 ruthenium Inorganic materials 0.000 claims 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000004907 flux Effects 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 15
- 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 102100036537 von Willebrand factor Human genes 0.000 description 8
- 239000012190 activator Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000007885 magnetic separation Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical class C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 238000002038 chemiluminescence detection Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000022774 Congenital thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- -1 Succinimidoyl Chemical group 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Abstract
The invention relates to the technical field of immunodetection analysis, in particular to an ADAMTS13 enzyme activity luminescence immunodetection method and an ADAMTS13 enzyme activity detection kit. The invention provides a luminescent immune detection method for ADAMTS13 enzyme activity, which adopts the principle of combining a chemiluminescent detection technology and a magnetic particle immune separation technology to quantitatively detect ADAMTS13 enzyme activity in human serum or plasma samples, has no pollution, strong specificity and simple operation, has low pretreatment requirement on the samples, can rapidly detect a large number of samples at high flux, is convenient for clinical practical application, and provides a more accurate, convenient and rapid method for detecting ADAMTS13 enzyme activity in the samples clinically.
Description
Technical Field
The invention relates to the technical field of immunodetection analysis, in particular to an ADAMTS13 enzyme activity luminescence immunodetection method and an ADAMTS13 enzyme activity detection kit.
Background
ADAMTS13 is a metalloprotease, mainly expressed in hepatic stellate cells, that specifically cleaves macromolecular von willebrand factor (von willebrand factor, VWF) multimers with thrombogenic effects. ADAMTS13 deficiency can lead to the continued presence of ultra-large molecular VWF multimers (UL-VWFM) in blood vessels, inducing platelet aggregation, and triggering Thrombotic Thrombocytopenic Purpura (TTP).
ADAMTS13 enzymatic activity in healthy adult human plasma is about 50% -178%, ADAMTS13 activity is completely absent or severely reduced (< 5%) in congenital TTP patients, and thus ADAMTS13 enzymatic activity is of great value as an indicator of TTP diagnosis and prognosis evaluation. In recent years, various methods have been used to determine the activity and inhibitors of plasma ADAMTS13, which can be largely divided into 2 types:
the first type, which determines its cleavage of vWF multimers under denaturing conditions (e.g., low concentration urea or guanidine hydrochloride), can be performed directly by gel electrophoresis, but this method is time-consuming and labor-intensive and can only be performed in a professional laboratory.
In the second type, the activity of the 73 amino acid peptide fragment of vWF-A2 domain is measured by taking the 73 amino acid peptide fragment as a substrate of ADAMTS13, and the method has better detection effect, but has the defects of complex operation and poor stability of the shorter amino acid peptide fragment. Currently, the measurement methods mainly include Fluorescence Resonance Energy Transfer (FRETS) method, enzyme-linked immunosorbent assay (ELISA) method and the like. FRETS is cumbersome in steps, expensive in reagents, and monopolized by commercial companies. ELISA has long detection time, complex operation and poor repeatability.
Therefore, a rapid quantitative detection method for ADAMTS13 enzyme activity with high sensitivity, simple operation, high automation degree and low cost is still needed.
Disclosure of Invention
In order to fill the blank of the prior art, the invention provides an ADAMTS13 enzyme activity luminescence immunoassay method and an ADAMTS13 enzyme activity assay kit. Specifically, the invention provides the following technical scheme:
in a first aspect, the invention provides an ADAMTS13 enzyme activity luminescence immunoassay kit.
According to some embodiments of the invention, the invention provides a kit for determining ADAMTS13 enzyme activity, the kit comprising reagent a, reagent B, reagent C, calibrator, quality control, and luminescent substrate solution. Wherein the reagent A comprises an A2 domain protein of VWF with specific tag sequences at both ends of C, N, the reagent B comprises a C-terminal specific tag sequence capable of binding to the A2 domain of VWF, the reagent C comprises an N-terminal specific tag sequence capable of binding to the A2 domain of VWF, the luminescent substrate solution comprises a substrate buffer solution capable of catalyzing luminescence of the reagent B, the calibrator comprises a series of gradient concentrations of ADAMTS13 enzyme, and the quality control comprises a determined concentration of ADAMTS13 enzyme.
According to some embodiments of the invention, the buffer of reagent a, reagent B, reagent C, calibrator, quality control, luminescent substrate solution comprises one or a combination of several selected from phosphate buffer, carbonate buffer, tris buffer, citrate buffer at ph6.0-9.0 at 10-100 mm.
According to some embodiments of the invention, the magnetic particles in the reagent C comprise composite microspheres formed by ferric oxide or ferroferric oxide magnetic nanoparticles and an organic polymer material, wherein the surfaces of the composite microspheres are modified to carry one or more active groups, and the active groups can be crosslinked with amino groups or carboxyl groups of the antibodies through amide bonds to form the magnetic particles coated with the antibodies.
According to some embodiments of the invention, the reagent C may be coated on the magnetic particles by coupling the amino or carboxyl groups of the antibody directly or via an intermediate linking compound to the surface of the magnetic beads, such as by indirect coating of the magnetic bead-streptavidin-coupled-biotin carrier protein, or may be indirectly attached to the magnetic particles in the reaction in the form of an antibody.
According to some embodiments of the invention, the concentration of the antibody labeled per milligram of magnetic particles is preferably between 1 and 20. Mu.g, the particle size of the magnetic particles is preferably between 0.5 and 10. Mu.m, and the concentration of the magnetic particles is preferably between 0.1 and 2 mg/ml.
According to some embodiments of the invention, the label in reagent B comprises any substance known in the art that can label an antibody, such as biotin-labeled, enzyme-labeled, in particular, when alkaline phosphatase (ALP) labeled, the substrate solution used comprises 0.005% -0.05% concentration of 9, 10-dihydroacridine derivative or 0.005% -0.05% concentration of adamantane derivative, and when the substrate is catalytically cleaved by the alkaline phosphatase (ALP), an unstable excited intermediate is formed, and when the excited intermediate returns to the ground state, photons are emitted to form a luminescence reaction, and the luminescence intensity of the reaction can be detected using a luminometer.
According to some embodiments of the invention, the antibody of reagent B comprises a monoclonal or polyclonal antibody obtained by any method known in the art, e.g., a monoclonal or polyclonal antibody produced by immunizing an animal with GST protein.
According to some embodiments of the invention, the label in reagent B is conjugated to an antibody via an amide bond to form a label-antibody B conjugate.
According to some more specific embodiments of the invention, the method of coupling the label-antibody B conjugate in reagent B comprises any method known in the art, for example, adding the commonly used activator 2-Iminothiolane hydrochloride (2-IT) in the art to the antibody B, adding the commonly used activator Succinimidomyl 4- (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) to the label, and mixing the activated label and antibody B in a ratio of preferably 1:0.5-2.
According to some embodiments of the invention, the standard curve is obtained by a method comprising:
(1) Immune response: sequentially adding 50 μl of the reagent A, 50 μl of the reagent B and 50 μl of the reagent C into a reaction tube, and mixing and incubating at 37deg.C for 10 min;
(2) Enzyme digestion reaction: adding 50 μl of sample or quality control material or calibrator into the reaction tube, and mixing and incubating at 37deg.C for 10 min;
(3) Magnetic separation: settling the magnetic particles in a magnetic field, removing the supernatant, adding 200-500 mu l of cleaning liquid, removing the magnetic field, settling the magnetic particles in the magnetic field again, and removing the supernatant; repeating the steps for 2-4 times to remove unbound antibodies and impurities;
(4) Reading: adding 200 μl of luminescent substrate solution, and measuring relative luminous intensity by full-automatic chemiluminescence immunoassay after alkaline phosphatase catalyzes substrate luminescence;
(5) Four parameter equation fitting was used to obtain an ADAMTS13 enzyme activity-luminescence standard curve based on the values detected.
In a second aspect, the invention provides a use of an ADAMTS13 enzyme activity luminescence immunoassay kit in detection of ADAMTS13 enzyme activity.
According to some specific embodiments of the invention, the specific steps of the detection kit in the detection of ADAMTS13 enzymatic activity comprise:
(1) Immune response: sequentially adding 50 μl of the reagent A, 50 μl of the reagent B and 50 μl of the reagent C into a reaction tube, and mixing and incubating at 37deg.C for 10 min;
(2) Enzyme digestion reaction: adding 50 μl of sample or quality control material or calibrator into the reaction tube, and mixing and incubating at 37deg.C for 10 min;
(3) Magnetic separation: settling the magnetic particles in a magnetic field, removing the supernatant, adding 200-500 mu l of cleaning liquid, removing the magnetic field, settling the magnetic particles in the magnetic field again, and removing the supernatant; repeating the steps for 2-4 times to remove unbound antibodies and impurities;
(4) Reading: 200 μl of luminescent substrate solution is added, the alkaline phosphatase catalyzes the substrate luminescence, and then the relative luminescence intensity is measured by a full-automatic chemiluminescence immunoassay instrument, and the ADAMTS13 enzyme activity in the sample is obtained through calculation.
In a third aspect, the invention provides a luminescent immunoassay for ADAMTS13 enzymatic activity.
According to some embodiments of the present invention, an ADAMTS13 enzyme activity luminescence immunoassay method is provided, wherein a magnetic particle separation technique is combined with a chemiluminescent immunoassay system to quantitatively detect ADAMTS13 enzyme activity in a sample.
According to some more specific embodiments of the invention, the ADAMTS13 enzyme activity luminescence immunoassay method specifically comprises:
1. coupling the C-terminal tag antibody C with the magnetic particles, and coating the magnetic particles with the C-terminal tag antibody C to prepare a reagent C;
2. labeling the N-terminal tag antibody B with a detectable marker to prepare a reagent B;
3. mixing the reagent A, the reagent C and the reagent B in proportion and then carrying out immune reaction;
4. mixing the immune complex with a sample to be detected for reaction, magnetically separating the immune complex from other substances, collecting magnetic particle sediment, adding a substrate for enabling a marker to emit light, and obtaining an ADAMTS13 enzyme activity-luminescence value standard curve;
5. the ADAMTS13 enzyme activity was calculated according to a standard curve.
The magnetic particle-connected antibody C is combined with the N-terminal label in the reagent A, the C-terminal label in the reagent A is combined with the antibody B marked by the marker to form an immune complex, and ADAMTS13 enzyme in a sample to be detected or a calibrator or a quality control product is subjected to enzyme digestion reaction with the immune complex. And then directly precipitating in an externally applied magnetic field, and magnetically separating the complex formed by the immune reaction from other unbound substances. The precipitated complex is washed after removal of the supernatant and the substrate solution is added. The substrate is catalytically cleaved to emit light under the action of the enzyme, the light intensity is inversely proportional to the ADAMTS13 enzyme activity in the sample, and the ADAMTS13 enzyme activity in the sample can be calculated by fitting using a four-parameter equation.
According to some embodiments of the invention, the magnetic particles comprise composite microspheres formed by ferric oxide or ferroferric oxide magnetic nanoparticles and an organic polymer material, wherein the surfaces of the composite microspheres are modified to carry one or more active groups, and the active groups can be crosslinked with amino groups or carboxyl groups of the antibody C through amide bonds to form the magnetic particles coated by the antibody C.
According to some embodiments of the invention, the reagent C may be coated on the magnetic particles by coupling the amino or carboxyl groups of the antibody C directly or via an intermediate linking compound to the surface of the magnetic beads, such as by indirect coating of the magnetic beads-streptavidin-coupled-biotin carrier protein, or may be directly attached to the magnetic particles in the reaction in the form of an antibody.
According to some embodiments of the invention, reagent A, reagent C, reagent B are mixed in proportion and then subjected to an immune reaction. According to some embodiments of the invention, the concentration of the antibody C per milligram of the magnetic particle label is preferably between 1 and 20. Mu.g, the particle size of the magnetic particle is preferably between 0.5 and 10. Mu.m, and the concentration of the magnetic particle is preferably between 0.1 and 2 mg/ml.
According to some embodiments of the invention, the label of the label-labeled antibody B comprises any substance known in the art that can label an antibody, such as biotin-labeled, enzyme-labeled, in particular, when alkaline phosphatase (ALP) labeled is used, the substrate solution used comprises 0.005% -0.05% concentration of 9, 10-dihydroacridine derivative or 0.005% -0.05% concentration of adamantane derivative, and when the substrate is catalytically cleaved under the action of alkaline phosphatase (ALP), an unstable excited intermediate is formed, photons are emitted when the excited intermediate returns to the ground state, and a luminescence reaction is formed, and the luminescence intensity of the reaction can be detected using a luminometer.
According to some embodiments of the invention, the antibodies in the reagent include monoclonal or polyclonal antibodies obtained by any method known in the art, e.g., monoclonal or polyclonal antibodies generated by immunizing an animal with a GST protein.
According to some embodiments of the invention, the label is an antibody B conjugate, which is a label formed by coupling the label to the antibody B via an amide bond.
According to some more specific embodiments of the invention, the method of coupling the label-antibody B conjugate comprises any method known in the art, for example, adding the commonly used activator 2-Iminothiolane hydrochloride (2-IT) to the antibody B, adding the commonly used activator Succinimidoyl 4- (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) to the label, and mixing the activated label and the antibody B in a ratio of preferably 1:0.5-2.
Compared with the prior art, the invention has the following beneficial technical effects:
1. the magnetic particle chemiluminescence immunoassay kit for detecting the ADAMTS13 enzyme activity can be combined with a full-automatic chemiluminescence analyzer, so that the operation steps are greatly simplified, the detection speed and the detection flux are improved, the detection efficiency is improved, and meanwhile, errors caused by manual operation are avoided. The detection sensitivity is ensured by quantitatively detecting ADAMTS13 enzyme activity in human serum or plasma samples by utilizing the principle of combining a chemiluminescent detection technology and a magnetic particle immunoseparation technology, and the kit is pollution-free, high in specificity, simple to operate, low in pretreatment requirement on samples, capable of rapidly detecting a large number of samples in high flux, capable of meeting clinical detection requirements, and capable of providing a more accurate, precise, convenient, rapid and simple method for clinically detecting ADAMTS13 enzyme activity.
2. The invention utilizes the principle of combining the chemiluminescence detection technology and the magnetic particle immune separation technology to quantitatively detect ADAMTS13 enzyme activity in the sample, ensures the detection sensitivity, has no pollution, strong specificity and simple operation because the magnetic particle separation and cleaning are adopted in the experiment, has low pretreatment requirement on the sample, can rapidly detect a large number of samples with high flux, and meets the clinical detection requirement. The invention provides a more accurate, precise, convenient, quick and simple method for clinically detecting the ADAMTS13 enzyme activity in the sample.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
The foregoing and/or additional aspects and advantages of the invention will become apparent and may be better understood from the following description of embodiments taken in conjunction with the accompanying drawings in which:
FIG. 1 shows a flow chart of a chemiluminescent immunoassay method for separating magnetic particles for ADAMTS13 enzymatic activity in an example.
Detailed Description
Embodiments of the present invention are described in detail below. The following examples are illustrative only and are not to be construed as limiting the invention.
In order that the invention may be more readily understood, certain technical and scientific terms are defined below. Unless clearly defined otherwise elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention belongs.
In the present invention, the term "antibody" refers to an antibody that can be immobilized on the surface of magnetic particles by physical adsorption for binding to an antigen to be measured. The antibody is bound to the magnetic particles through the functional groups to form the immunomagnetic beads, and the antibody and the corresponding antigen have high affinity, so that the antibody and the antigen can be bound together and fixed on the magnetic particles for detection.
In the present invention, the term "label" refers to an antibody obtained by enzymatic labeling or by colloidal gold labeling of an antibody, which is a means for observing research on the aspect of an antigen-antibody immune complex, in a method for preparing an immunoelectron microscope sample. The immunolabeling technique is to label substances which are easy to measure and have high sensitivity to specific antigen or antibody molecules, and the property and the content of the antigen or antibody in a reaction system are shown by the enhanced amplification effect of the labels. Antibodies are mainly used for localization analysis of antigens, and in some cases, can also be used for quantitative detection of antigens in samples mixed with a large number of other molecules. Because antibodies have high affinity for their corresponding antigens, antibodies with readily identifiable labels can localize the analyte antigen and are an ideal, rapid and inexpensive quantitative assay.
In the present invention, the term "alkaline phosphatase" (Alkaline Phosphatase, ALP) has a molecular weight of 140,000Da and is mainly used in molecular biology and protein research to remove 5' -phosphate groups from DNA or as a reporter system for immunoassays. In immunoassay tests, enzymes are typically bound to specific primary or secondary antibodies, the activity of which is detected with chromogenic (or luminescent) substrates.
In the present invention, the term "magnetic particles" refers to colloidal composite materials that can be uniformly dispersed in a certain base liquid. Because of the characteristics of superparamagnetism, higher specific surface area, modifiable functional groups and the like, antigens/antibodies, enzymes, nucleic acid/oligonucleotides, small molecule drugs and the like are immobilized on the surfaces of the antibodies.
The enzyme-linked immunosorbent assay (enzyme linked immunosorbent assay, ELISA) is a detection method which uses the characteristic that an antibody molecule can specifically bind to an antigen molecule to combine free hybrid protein with target protein bound to a solid carrier and uses a special marker to perform qualitative or quantitative analysis on the hybrid protein.
The aspects of the present disclosure will be explained below with reference to examples. Those skilled in the art will appreciate that the following examples are illustrative of the present disclosure and should not be construed as limiting the scope of the present disclosure. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
All components of the detection kit of the present invention are commercially available from biological or chemical reagent companies. The labeled alkaline phosphatase (ALP) used in the present invention is available from BBI, inc., model number, UK: ALPI12G; SMCC is available from thermo fisher scientific company under the number: 22360;2-IT was purchased from thermo fisher scientific, CAS:4781-83-3; cargo number: 26101; carboxyl modified microparticles were purchased from JSR Life Sciences company; EDC is available from SIMGA, CAS:25952-53-8, cat No.: E7750.
example 1: preparation of reagent A
The His-tagged product was purified by Ni-NTA Superflow (Qiagen) chromatography steps using a plasmid carrying the coding gene of GST-VWFA2-HIS (amino acid sequence shown in SEQ ID NO. 1) for transient gene expression in Human Embryonic Kidney (HEK) 293 cells. The final purified protein product was measured to a concentration of 2mg/ml by UV spectrophotometry and diluted to 100ng/ml with 10mM PBS as reagent A for use.
Example 2: preparation of reagent B
1.0mg of GST protein antibody (MA 4-004, invitrogen) was concentrated to 2.5mg/ml, 5. Mu.l of activator 2-Iminothiolane hydrochloride (2-IT) solution at a concentration of 13.76mg/ml was added thereto, and the mixture was reacted at room temperature for 15 minutes. The activated antibodies were collected using Sephadex G25 gel column for desalting.
1.2mg of alkaline phosphatase was concentrated to 2.5mg/ml, 12. Mu.l of a solution of 6.69mg/ml of the activator Succinimidodyn 4- (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) in water was added, and the mixture was reacted at room temperature for 15 minutes. The alkaline phosphatase was collected after desalting using a Sephadex G25 gel column.
The activated GST protein antibody was mixed with alkaline phosphatase in a ratio of 1.0mg of GST protein antibody to 1.0mg of alkaline phosphatase, and allowed to react at 4℃for 18 hours.
The solution was separated and purified by using a Supperdex200 gel column, and the unbound GST protein antibody and alkaline phosphatase were removed, and the ligation mixture was stored at 4℃to prepare reagent B.
Example 3: preparation of reagent C
Taking 20mg of Carboxyl modified particle solution (manufacturer: JSR Life Sciences Corporation; product number: MS300/Carboxyl; specification: 3 um), settling (magnetic separation) magnetic particles with superparamagnetism and uniform particle size and Carboxyl (COOH-) active groups on the surface under the action of a magnetic field for 10 minutes, removing supernatant, and washing the settled magnetic particles with (2- (N-morpholino) ethanesulfonic acid) MES with the molar concentration of an activation buffer solution of 0.05M for 3 times by using 2ml of buffer solution with the pH of 6.0.
After washing, the magnetic particles were sufficiently suspended in 1.0ml of (2- (N-morpholino) ethanesulfonic acid) MES at a molar concentration of 0.05M in a buffer solution at pH6.0, and then 1-ethyl-3- [ 3-dimethyllaminopyyl ] carbodiimide hydrochloride (EDC) as an activator was added thereto, followed by suspension reaction at room temperature for 30 minutes at an EDC molar concentration of 7.5mM.
1.0mg of HIS tagged protein antibody was taken and concentrated to 2.5mg/ml.
And adding the HIS tag protein antibody concentrated to 2.5mg/ml into 20mg of activated magnetic particle solution according to 1.0mg of the HIS tag protein antibody, mixing the mixture, stirring the mixture gently, and reacting the mixture for 6.5 hours under the suspension condition of 4 ℃ to enable the HIS tag protein antibody to be covalently coupled on the surface of the magnetic particles, thereby preparing the reagent C.
Example 4: ADAMTS13 enzyme activity magnetic particle separation chemiluminescence immunoassay method
The flow of the detection method is shown in fig. 1, and specifically comprises the following steps:
(1) Immune response: sequentially adding 50 μl of the reagent A, 50 μl of the reagent B and 50 μl of the reagent C into a reaction tube, and mixing and incubating at 37deg.C for 10 min;
(2) Enzyme digestion reaction: 50 μl of calibrator was added to the reaction tube and incubated for 10 min at 37deg.C;
(3) Magnetic separation: settling the magnetic particles in a magnetic field, removing the supernatant, adding 200-500 mu l of cleaning liquid, removing the magnetic field, settling the magnetic particles in the magnetic field again, and removing the supernatant; repeating the steps for 2-4 times to remove unbound antibodies and impurities;
(4) Reading: adding 200 μl of luminescent substrate solution, and measuring relative luminous intensity by full-automatic chemiluminescence immunoassay after alkaline phosphatase catalyzes substrate luminescence; (5) Fitting according to the detected values by using a four-parameter equation to obtain an ADAMTS13 enzyme activity-luminescence value standard curve;
(6) Immune response: sequentially adding 50 μl of the reagent A, 50 μl of the reagent B and 50 μl of the reagent C into a reaction tube, and mixing and incubating at 37deg.C for 10 min;
(7) Enzyme digestion reaction: 50 μl of the sample was added to the reaction tube and incubated for 10 minutes at 37deg.C with mixing;
(8) Magnetic separation: settling the magnetic particles in a magnetic field, removing the supernatant, adding 200-500 mu l of cleaning liquid, removing the magnetic field, settling the magnetic particles in the magnetic field again, and removing the supernatant; repeating the steps for 2-4 times to remove unbound antibodies and impurities;
(9) Reading: adding 200 μl of luminescent substrate solution, and measuring relative luminous intensity by full-automatic chemiluminescence immunoassay after alkaline phosphatase catalyzes substrate luminescence;
(10) And (3) comparing the luminous intensity of the sample to be detected with the standard curve in the step (5), and calculating the ADAMTS13 enzyme activity in the sample to be detected by using four-parameter equation fitting.
Example 5: kit performance test
The kit is used together with a full-automatic chemiluminescence analyzer to detect 29 cases of TTP patient plasma samples with low ADAMTS13 enzyme activity and 20 cases of normal human plasma samples, the detection luminescence values are shown in Table 1, and the detection results of the TTP patient samples and the detection results of the normal human plasma samples are subjected to t-test detection analysisP<0.01, the two groups have significant differences. The kit can provide help for timely diagnosis and treatment of related ADAMTS13 enzyme activity abnormal diseases.
Table 1 results of testing clinical samples with the kit
The magnetic particle chemiluminescence detection kit for ADAMTS13 enzyme activity can be combined with a full-automatic chemiluminescence analyzer, so that the operation steps are greatly simplified, the detection speed and the detection flux are improved, the detection efficiency is improved, and meanwhile, errors caused by manual operation are avoided.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (19)
1. An ADAMTS13 enzyme activity luminescence immunoassay kit is characterized by comprising a reagent A, a reagent B, a reagent C and a luminescence substrate solution;
wherein the reagent A comprises an A2 domain protein of VWF with specific tag sequences at two ends of C, N;
the agent B comprises a C-terminal specific tag sequence capable of binding to the A2 domain of VWF;
the agent C comprises an N-terminal specific tag sequence capable of binding to the A2 domain of VWF;
and wherein reagent B is labeled with a detectable label,
and wherein the reagent C is capable of being immobilized on the magnetic particles.
2. The kit of claim 1, wherein the A2 domain of VWF having a specific tag sequence at both ends of C, N is a D1459 to R1668 amino acid sequence cleavable by ADAMTS13,
wherein the Tag sequence comprises c-Myc, aviTag, SNAP-Tag, strep-Tag II, GST and 6His;
wherein the C, N ends carry different labels as described above;
wherein the reagent B and the reagent C are antibodies, the reagent B specifically recognizes one tag sequence, and the reagent C specifically recognizes the other tag sequence.
3. The kit according to claim 1, wherein the magnetic particles have a particle size of not more than 10 μm.
4. A kit according to claim 3, wherein the magnetic particles have a particle size of 0.5-10 μm.
5. The kit of claim 1, wherein the label is a biological or chemical label, the biological enzyme comprising at least one of horseradish peroxidase, alkaline phosphatase; the chemical marker includes at least one of acridinium ester, ruthenium terpyridyl, isoluminol and derivatives thereof.
6. The kit of claim 1, wherein the luminescent substrate solution comprises a buffer solution of a substrate capable of catalyzing the luminescence of reagent B.
7. The kit of claim 1, wherein the kit further comprises a calibrator and/or a quality control,
wherein the calibrator comprises ADAMTS13 enzymes of different gradients of activity;
the quality control includes a buffer solution for determining activity of an ADAMTS13 enzyme.
8. The kit according to claim 6 or 7, wherein the buffer solution comprises at least one selected from the group consisting of phosphate buffer, carbonate buffer, tris buffer, citrate buffer.
9. The kit of claim 1, wherein the kit further comprises a calibrator and/or a quality control,
wherein the calibrator comprises ADAMTS13 enzymes of different gradients of activity;
the quality control includes a buffer solution for determining activity of an ADAMTS13 enzyme.
10. Use of the ADAMTS13 enzyme activity immunoassay kit of any one of claims 1-9 in an ADAMTS13 enzyme activity assay.
11. An ADAMTS13 enzyme activity luminescence immunoassay method, characterized in that the assay method comprises performing ADAMTS13 enzyme activity assay on a sample to be assayed using the ADAMTS13 enzyme activity luminescence immunoassay kit of any one of claims 1 to 9.
12. An ADAMTS13 enzyme activity luminescence immunoassay method, comprising:
(A) Coupling the C-terminal tag antibody C with the magnetic particles, and coating the magnetic particles with the C-terminal tag antibody C to prepare a reagent C;
(B) Labeling the N-terminal tag antibody B with a detectable marker to prepare a reagent B;
(C) Mixing the reagent A, the reagent B and the reagent C to perform immune reaction to form immune complex;
(D) Mixing the immune complex with a sample to be tested, magnetically separating the immune complex from other substances, and collecting magnetic particle sediment;
(E) Adding a luminescent substrate solution into the magnetic particle precipitate, and detecting the luminescence intensity so as to obtain the ADAMTS13 enzyme activity in the sample to be detected.
13. The method of detection of claim 12, wherein the method of detection further comprises:
an ADAMTS13 enzyme activity-luminescence value standard curve was plotted using a calibrator, wherein the calibrator comprises different gradients of ADAMTS13 enzyme activity.
14. The method of detecting according to claim 13, further comprising:
(1) Taking a calibrator as a sample to be tested, and implementing the steps (A) - (E), and determining luminous intensities corresponding to different concentrations, wherein the calibrator comprises ADAMTS13 enzyme activities with different gradients;
(2) Drawing an ADAMTS13 enzyme activity-luminescence value standard curve according to the luminescence intensity;
(3) And obtaining the ADAMTS13 enzyme activity in the unknown sample to be tested according to the ADAMTS13 enzyme activity-luminescence value standard curve.
15. The method according to claim 12, wherein the magnetic particles have a particle diameter of not more than 10 μm.
16. The method according to claim 12, wherein the magnetic particles have a particle diameter of 0.5 to 10. Mu.m.
17. The method according to claim 12, wherein the label comprises any one of a biological enzyme, a fluorescein, and a chemiluminescent label.
18. The method of claim 17, wherein the biological enzyme comprises at least one of horseradish peroxidase and alkaline phosphatase.
19. The method of detecting according to claim 17, wherein the chemiluminescent label comprises at least one of an acridinium ester, ruthenium terpyridyl, isoluminol, and derivatives thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410044447.2A CN117554615A (en) | 2024-01-12 | 2024-01-12 | ADAMTS13 enzyme activity luminescence immunoassay method and ADAMTS13 enzyme activity assay kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410044447.2A CN117554615A (en) | 2024-01-12 | 2024-01-12 | ADAMTS13 enzyme activity luminescence immunoassay method and ADAMTS13 enzyme activity assay kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117554615A true CN117554615A (en) | 2024-02-13 |
Family
ID=89820897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410044447.2A Pending CN117554615A (en) | 2024-01-12 | 2024-01-12 | ADAMTS13 enzyme activity luminescence immunoassay method and ADAMTS13 enzyme activity assay kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117554615A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008131908A (en) * | 2006-11-29 | 2008-06-12 | Mitsubishi Kagaku Iatron Inc | Method for analyzing von willebrand factor-decomposing enzyme |
| US20090075298A1 (en) * | 2005-05-20 | 2009-03-19 | Mitsubishi Kagaku Iatron, Inc. | Method of analyzing enzyme |
-
2024
- 2024-01-12 CN CN202410044447.2A patent/CN117554615A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075298A1 (en) * | 2005-05-20 | 2009-03-19 | Mitsubishi Kagaku Iatron, Inc. | Method of analyzing enzyme |
| JP2008131908A (en) * | 2006-11-29 | 2008-06-12 | Mitsubishi Kagaku Iatron Inc | Method for analyzing von willebrand factor-decomposing enzyme |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200096502A1 (en) | Analyte Detection | |
| US8029985B2 (en) | Amplified bioassay | |
| JP3863493B2 (en) | Immunoassay method | |
| AU679008B2 (en) | Mixed luminescent conjugate test assays | |
| JP2019191187A (en) | Reagent for detecting target matter, detecting method, carrier used for detecting target matter, and manufacturing method thereof | |
| WO2006123789A1 (en) | Method of analyzing enzyme | |
| EP2786150B1 (en) | Detection of multiple analytes | |
| KR101548284B1 (en) | A Novel Method for Detecting an Analyte and Kits Using It | |
| JPH03123498A (en) | Fibrinolytic measurement | |
| CN111693721A (en) | Preparation method and application of enzyme-linked immunosorbent assay based on prussian blue nano enzyme label | |
| WO2004048975A1 (en) | Method of examining staphylococcus aureus | |
| KR20010025027A (en) | Immunoassay reagents and immunoassay method | |
| JP2892879B2 (en) | Methods for measuring high molecular weight analytes | |
| Li et al. | CRISPR/Cas12a-based fluorescence immunoassay: combination of efficient signal generation with specific molecule recognition | |
| CN117554615A (en) | ADAMTS13 enzyme activity luminescence immunoassay method and ADAMTS13 enzyme activity assay kit | |
| CN112708660B (en) | CRISPR-POCT detection composition and application thereof | |
| Kong et al. | A novel sensitive immunoassay by nucleic acid barcode dot and its application in the detection of prostate-specific antigen | |
| CN116381222A (en) | Serotonin luminescent immune detection method and serotonin detection kit | |
| WO2004048976A1 (en) | Method of inspecting staphylococcus aureus | |
| JP2018500900A (en) | Activity assay for bond-forming enzymes | |
| JPH11311624A (en) | Assay surface enabling analysis material liberation stage | |
| CN113933497A (en) | I type collagen amino-terminal extension peptide magnetic particle chemiluminescence immunoassay kit and detection method thereof | |
| CN114609379A (en) | Detection reagent and detection method for 3-methoxytyramine | |
| CN117890575A (en) | Microsphere-free homogeneous chemiluminescence detection method for detecting nerve factors | |
| JP5143046B2 (en) | Test substance measurement method and kit for carrying out the measurement method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |